Abstract Aims-The aims of this study were to report local tumour control after transscleral local resection of uveal melanoma and to identify risk factors for (i) clinical residual tumour recognised immediately after surgery, and (ii) delayed tumour recurrence from subclinical microscopic deposits. Methods-The sample included 310 patients, treated by choroidectomy (188), cyclochoroidectomy (87), or iridocyclectomy (35), with follow up ranging from 42 days to 20-9 years (median 36 months), a mean basal largest tumour diameter of 13*2 mm, and a mean tumour thickness of 7'4 mm. Results-There were 24 patients with residual tumour. Forward stepwise logistic regression indicated that posterior extension to within 1 disc diameter of the optic disc or fovea was the sole best indicator of the risk of residual disease (p<0.001). After excluding these cases, 286 patients were studied for the development of delayed local recurrence, which occurred in 57 cases. Forward stepwise multivariate analysis showed the statistically significant predictors for recurrent tumour to be epithelioid cellularity (p=0002), posterior tumour extension to <1 disc diameter of disc of fovea (p=0.002), large tumour diameter >16 mm (p=0-019) and lack of adjunctive plaque radiotherapy (p=0.018).
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Conclusions-The recurrence rate at 4 years varied from 6% if no risk factors were present to 57°/0 if there were more than two risk factors. (BrJr Ophthalmol 1996; 80: 102-108) Uveal melanoma is a rare malignant neoplasm with an overall 10 year mortality of approximately 50%. 1 For many years, the standard way of eliminating the source of metastases was enucleation, but now there is increasing interest in conserving the eye and vision by a variety of methods, which include brachytherapy,24 teletherapy,4 6 and trans-scleral local resection.7-9 Trans-scleral local resection is technically difficult and is, therefore, performed in only a few centres, where it is reserved for tumours that are deemed to be unsuitable for plaque or proton beam radiotherapy.10 Previous studies show that conservation of the eye and vision is possible when a choroidal tumour does not extend very close to optic disc or fovea,"I and when a ciliary body tumour is small.12 One of the main complications of trans-scleral local resection is incomplete tumour removal, which manifests either immediately as visible residual tumour at the end of the operation or after a delay of months or years when recurrent tumour arises from invisible microscopic tumour deposits.
Residual and recurrent tumours after transscleral local resection follow retinal detachment as the commonest causes of visual loss and enucleation'1 and are also associated with an increased incidence of metastasis.'3 The aims of this study were to identify the risk factors for clinical residual tumour and delayed tumour recurrence so that these complications might be avoided.
Patients, materials, and methods PREOPERATIVE ASSESSMENT Our methods of preoperative assessment are described elsewhere.'0" The following data were obtained at the time of treatment or subsequently by reviewing photographs and records: (i) patient age and sex; (ii) Snellen visual acuity measured with spectacles, pinhole, or unaided as clinically indicated; (iii) tumour height and largest and smallest basal tumour diameters as measured by B-scan ultrasonography; (iv) location of anterior and posterior margins of the tumour; and (v) coronal and sagittal location of the tumour. The tumour was said to have 'posterior tumour extension' if its posterior margin was situated within 1 disc diameter of the disc margin or fovea. The coronal location of the tumour was categorised as 'vertical' if the 'centre of gravity' of the tumour was located on a vertical line passing through the fovea, and 'nasal' or 'temporal' if the tumour was placed medial or lateral to the fovea.
SURGICAL TECHNIQUE
The surgical techniques are described in detail elsewhere.'0 Briefly, a rectangular lamellar scleral flap was dissected over the tumour, after defining the tumour margins by transpupillary transillumination. The deep sclera and choroid were divided some 3-5 mm from the tumour, which was removed avoiding retinal damage whenever possible. Residual tumour was defined as any clinical tumour diagnosed in the first 40 postoperative days. The time period of 40 days was selected because in some patients the fundus could not be examined until the first postoperative visit, which was usually about 1 month after the operation. Recurrent tumour was defined as any clinical tumour diagnosed more than 40 days after apparently complete tumour resection.
Pearson's x2 test was used to identify important associations between presence of residual tumour and various individual prognostic factors. Logistic regression'6 was then used together with a forward stepwise procedure (p to enter=p to remove=0-05) to identify factors which jointly predict for the presence of residual tumour. A backward stepwise procedure was also carried out, giving the same model as the forward procedure, and therefore is not referred to specifically in the results section.
In relation to recurrent tumour, p values for the univariate comparisons of time to recurrent tumour between different groups were derived by fitting Cox Figure 5 shows the Kaplan-Meier survival curves which give the time to recurrent tumour according to the risk group. The incidence and the rate of appearance of recurrent tumour were related to the number of risk factors. In the absence of any risk factors, 94% of patients were free of local tumour recurrence 4 years postoperatively. When one risk factor was present, this figure fell to 86% and when three or four risk factors were present about 43% of patients were free of recurrent disease 3 years postoperatively.
Location
The recurrent tumours were nearly all located within or at the margin of the surgical coloboma.
In addition, intraocular metastases in distant parts of the eye were noted in nine patients. Sixteen eyes developed extraocular tumour extension. 
Outcome
Of the 57 patients with recurrent tumour, 27 (47%) retained the eye at the close of the study, after receiving secondary plaque radiotherapy (six), photocoagulation (nine), photocoagulation and radiotherapy (10) , cryotherapy, photocoagulation, and plaque (one), photocoagulation and endoresection (one). Twenty eight eyes were enucleated and one was exenterated. Loss of the eye occurred either in the first instance (15) or after further conservative treatment, which consisted of photocoagulation (seven), radiotherapy (two), photocoagulation and radiotherapy (two), cryotherapy photocoagulation and plaque (two), and a second local resection (one). Eleven patients received orbital irradiation for extraocular tumour extension. Table 4 shows the vision at the last patient visit according to residual tumour, recurrent tumour, and retinal detachment. In the absence of any of these complications, 97% of 174 eyes were retained, with 83% of eyes having vision of counting fingers or better, and 35% having vision of 6/12 or better. In the presence of persistent tumour and retinal detachment, then only 45% of eyes were retained, with none having vision better than 6/36. When only one type of complication occurred, the 50-60% of eyes were retained, with preservation of vision being more successful after treatment of intraocular tumour than after retinal detachment surgery. In the 81 patients with residual or recurrent tumour the rate of metastatic death was 27% compared with 13% in 229 patients without these complications. Survival in all cases and visual outcome after choroidectomy are reported separately in other studies," 13 with evaluation of visual outcome after cyclectomy still in progress. Discussion This is the largest study of residual and 106 group.bmj.com on November 7, 2017 -Published by http://bjo.bmj.com/ Downloaded from recurrent uveal melanoma after local resection yet reported, both in terms of number of patients and duration of follow up. The sample includes patients who were treated as early as 1969 before ruthenium plaque radiotherapy, laser photocoagulation, and vitrectomy were available to us, and before the treatment of retinal detachment had reached its present state of development. Furthermore, this sample includes patients operated on during the learning curves of two surgeons, in many cases with surgical techniques that have since been discontinued. For these reasons, the results reported in this study may not be representative of those that can now be achieved. Nevertheless, this study is useful because it identifies the risk factors for residual and recurrent disease so that appropriate preventive measures can be taken.
The overall incidence of clinical residual tumour was 8%. Residual tumour occurred more frequently with tumours extending far posteriorly because in these cases the placement of scissors posterior to the tumour was prevented by the optic nerve or excessive retinal bulging through the scleral window.
Recurrent tumour from microscopic deposits had an overall incidence of 32% at 7 years. No cases occurred more than 7 years postoperatively. Recurrence was most common after excision of large, posterior tumours containing epithelioid cells. This Comparisons between our data and those published by other workers are of limited significance because of the large number of confounding factors. Shields and associates report an 1 1% incidence of local tumour recurrence,9 but only 6% of all tumours were located entirely within the choroid compared with 61% in our sample so that our tumours were more difficult to resect. An evaluation of 107 iridocyclectomies performed by several surgeons showed that 15 eyes (14%) developed local tumour recurrence and that an additional nine eyes (8%) were enucleated because of incomplete excision.18 In comparison, only two (6%) of our patients developed recurrence after iridocyclectomy by the close of the study. Our results, therefore, seem to compare favourably with those of other workers.
We did not achieve statistically significant reductions in the rates of residual and recurrent tumour with ocular decompression or with year of operation. There are several possible reasons for this. Firstly, we probably attempted to resect more challenging cases as we gained more experience. In addition, until we became aware of the results of this study, we were misled (i) by the normal appearances of the choroid adjacent to the tumour when deciding where to place our scissors at surgery, and (ii) by the histological evidence of clearance when deciding whether or not to administer adjunctive treatment. Now, tumours are excised with wider clearance margins and, in addition, adjunctive plaque radiotherapy, laser photocoagulation and/or cryotherapy are applied irrespective of histological clearance. With regard to the management of residual or recurrent tumour, we no longer rely on ultrasonography for the diagnosis of persistent tumour and immediately perform enucleation if opaque media preclude proper examination of the fundus by ophthalmoscopy. In the event of residual or recurrent tumour we are more inclined to perform plaque radiotherapy instead of laser photocoagulation and we no longer rely on fluorescein angiography to assess tumour viability after treatment. '9 20 In the 46 patients who received adjunctive plaque radiotherapy, the rate of tumour recurrence was significantly lower than in the rest of the patients. This suggests that all patients should receive additional therapy, if possible. The placement of a radioactive plaque at the end of a local resection may be difficult or impossible if the scleral flap is very large or if external plombage has been applied, and may be undesirable if the eye has been filled with gas. Furthermore, radiotherapy may cause radiational optic neuropathy, maculopathy, or cataract. There are other ways of preventing tumour recurrence, such as (a) excising the tumour with wider clearance margins, with the aid of larger scleral openings and greater ocular decompression, and (b) adjunctive laser photocoagulation and cryotherapy. Further studies are required to determine whether such measures would be as effective as adjunctive radiotherapy.
Forty six per cent of eyes with residual or recurrent tumour were enucleated. There were various reasons for this outcome, which included (a) inability to eradicate residual tumour because of diffuse spread to the optic nerve, ciliary body, or orbit, and (b) other complications, such as retinal detachment, which may have been caused by the local resection or by the secondary treatment. Other complicating factors were present in the early years, such as (i) the lack of ruthenium plaque radiotherapy and laser photocoagulation, (ii) inexperience with laser these techniques were first introduced, (iii) excessive reliance on fluorescein angiography after photocoagulation and on ultrasonography for the detection of residual or recurrent tumour in disorganised eyes, and (iv) lack of experience in recognising early recurrences ophthalmoscopically. As a result, there were several patients in whom the recurrent tumour either was not recognised early, or was inadequately treated, or both, and a number of these patients went on to develop extraocular tumour extension. In another study, we show that bulky local tumour recurrence and extraocular tumour extension are associated with an increased risk of metastatic disease.'3 It is uncertain whether recurrence and metastasis shared a common cause or whether the recurrence was the source of the metastases; however, patients treated by local resection need close monitoring by an experienced surgeon, with prompt enucleation if adequate ophthalmoscopic examination is not possible because of irreversible ocular disorganisation or if residual disease cannot be treated effectively.
In conclusion, tumour extension to within 1 disc diameter of the optic disc or fovea increases the risk of visible residual tumour after trans-scleral local resection. Such posterior tumour extension is also a risk factor for delayed local tumour recurrence, with other adverse prognostic factors being basal tumour diameter of 16 mm or more, presence of epithelioid cells, and lack of adjunctive plaque radiotherapy. A 
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